sulfonylurea compounds

Summary

Top Publications

  1. ncbi 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
  2. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
  3. ncbi Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin
    Samantha L Bowker
    Institute of Health Economics, Edmonton, Alberta, Canada
    Diabetes Care 29:254-8. 2006
  4. ncbi Oral antidiabetic agents: current role in type 2 diabetes mellitus
    Andrew J Krentz
    Southampton University Hospitals NHS Trust, Southampton, UK
    Drugs 65:385-411. 2005
  5. ncbi Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
    Ewan R Pearson
    Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, United Kingdom
    N Engl J Med 355:467-77. 2006
  6. pmc Metformin and cancer occurrence in insulin-treated type 2 diabetic patients
    Matteo Monami
    Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Careggi Teaching Hospital, Florence, Italy
    Diabetes Care 34:129-31. 2011
  7. ncbi Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, UK
    Lancet 373:2125-35. 2009
  8. ncbi Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA, USA
    Diabetes Obes Metab 8:436-47. 2006
  9. ncbi Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis
    Jorge L Gross
    Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
    Ann Intern Med 154:672-9. 2011
  10. ncbi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    R C Turner
    Radcliffe Infirmary, Oxford, England
    JAMA 281:2005-12. 1999

Detail Information

Publications264 found, 100 shown here

  1. ncbi 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
    ..We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes...
  2. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  3. ncbi Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin
    Samantha L Bowker
    Institute of Health Economics, Edmonton, Alberta, Canada
    Diabetes Care 29:254-8. 2006
    ..We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer...
  4. ncbi Oral antidiabetic agents: current role in type 2 diabetes mellitus
    Andrew J Krentz
    Southampton University Hospitals NHS Trust, Southampton, UK
    Drugs 65:385-411. 2005
    ..However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals...
  5. ncbi Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
    Ewan R Pearson
    Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, United Kingdom
    N Engl J Med 355:467-77. 2006
    ..Diabetes results from impaired insulin secretion caused by a failure of the beta-cell K(ATP) channel to close in response to increased intracellular ATP. Sulfonylureas close the K(ATP) channel by an ATP-independent route...
  6. pmc Metformin and cancer occurrence in insulin-treated type 2 diabetic patients
    Matteo Monami
    Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Careggi Teaching Hospital, Florence, Italy
    Diabetes Care 34:129-31. 2011
    ..Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients...
  7. ncbi Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, UK
    Lancet 373:2125-35. 2009
    ..We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety...
  8. ncbi Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA, USA
    Diabetes Obes Metab 8:436-47. 2006
    ..This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET)...
  9. ncbi Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis
    Jorge L Gross
    Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
    Ann Intern Med 154:672-9. 2011
    ..Few studies have examined the effect of adding a third antihyperglycemic drug when blood glucose control is not achieved by using metformin and a sulfonylurea...
  10. ncbi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    R C Turner
    Radcliffe Infirmary, Oxford, England
    JAMA 281:2005-12. 1999
    ..8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown...
  11. pmc Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    D Russell-Jones
    Department of Diabetes and Endocrinology, Royal Guildford Hospital, UK
    Diabetologia 52:2046-55. 2009
    ..The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride...
  12. ncbi Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor
    S J Tucker
    University Laboratory of Physiology, Oxford, UK
    Nature 387:179-83. 1997
    ..We show here that the primary site at which ATP acts to mediate K-ATP channel inhibition is located on Kir6.2, and that SUR1 is required for sensitivity to sulphonylureas and diazoxide and for activation by Mg-ADP...
  13. ncbi Sulphonylureas and cancer: a case-control study
    Matteo Monami
    Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatrics, University of Florence and Azienda Ospedaliero Universitaria Careggi, Via delle Oblate 4, 50134, Florence, Italy
    Acta Diabetol 46:279-84. 2009
    ..In particular, the possible protective effect of gliclazide, as well as the risk associated with glibenclamide, deserves further investigation...
  14. ncbi Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
    Michael N Cook
    Department of Epidemiology, Merck Research Laboratories, Merck, BL 1 7, P O Box 4, West Point, PA 19486 0004, USA
    Diabetes Care 28:995-1000. 2005
    ..To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF)...
  15. ncbi Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
    D R Matthews
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital and NIHR, Oxford Biomedical Research Centre, UK
    Diabetes Obes Metab 12:780-9. 2010
    ..To show that vildagliptin added to metformin is non-inferior to glimepiride in reducing HbA1c levels from baseline over 2 years...
  16. ncbi Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
    Yan Gao
    Department of Endocrinology, Peking University First Hospital, Beijing, China
    Diabetes Res Clin Pract 83:69-76. 2009
    ..To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequately controlled with oral agents...
  17. ncbi Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase
    Akira Takahashi
    Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Diabetes Res Clin Pract 77:343-50. 2007
    ..These findings help to clarify the mechanism of secondary failure after long-term therapy by these hypoglycemic agents, and should have important clinical implications regarding pharmacotherapy for type 2 diabetes...
  18. ncbi Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    K Hermansen
    Aarhus University Hospital, Aarhus, Denmark
    Diabetes Obes Metab 9:733-45. 2007
    ..5% and <or=10.5%] while on glimepiride alone or in combination with metformin...
  19. ncbi Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction
    Marianne Zeller
    Laboratory of Experimental and Cardiovascular Physiopathology and Pharmacology, Institut Fédératif de Recherche Santé Sciences et Techniques de l Information et de la Communication, Faculty of Medicine, 7 bd Jeanne d Arc, Dijon, France
    J Clin Endocrinol Metab 95:4993-5002. 2010
    ....
  20. ncbi Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets
    Silvia Del Guerra
    Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital Pisa, Pisa 56100, Italy
    J Diabetes Complications 19:60-4. 2005
    ..In conclusion, prolonged exposure of human islets to different sulphonylureas causes different disturbances of islet cell function, with glimepiride showing milder effects, as compared with chlorpropamide and glibenclamide...
  21. ncbi Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study
    C Andersson
    Department of Cardiology, Gentofte University Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Diabetologia 53:2546-53. 2010
    ..We investigated the risk of all-cause mortality associated with individual glucose-lowering treatment regimens used in current clinical practice in Denmark...
  22. ncbi Mechanisms of the glycaemic effects of sulfonylureas
    F M Ashcroft
    University Laboratory of Physiology, Oxford
    Horm Metab Res 28:456-63. 1996
    ..Earlier studies are also re-examined in the light of new findings...
  23. pmc Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
    Michael Nauck
    Diabeteszentrum Bad Lauterberg, Harz, Germany
    Diabetes Care 32:84-90. 2009
    ..The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy...
  24. pmc National trends in treatment of type 2 diabetes mellitus, 1994-2007
    G Caleb Alexander
    Department of Medicine, Section of General Internal Medicine, The University of Chicago, Chicago, IL 60637, USA
    Arch Intern Med 168:2088-94. 2008
    ..Diabetes mellitus is common, costly, and increasingly prevalent. Despite innovations in therapy, little is known about patterns and costs of drug treatment...
  25. ncbi Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations
    Meena Rafiq
    Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, UK
    Diabetes Care 31:204-9. 2008
    ..2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations. We aimed to describe the response to sulfonylurea therapy in patients with SUR1 mutations and to compare it with Kir6.2 mutations...
  26. ncbi Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    John B Buse
    Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Care 27:2628-35. 2004
    ..This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy...
  27. ncbi Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin
    Chih Cheng Hsu
    Division of Health Policy Research and Development, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan, ROC
    J Alzheimers Dis 24:485-93. 2011
    ..T2DM increases the risk of dementia more than 2-fold. On the other hand, sulfonylureas may decrease the risk of dementia, as does metformin; together, these 2 OAs decrease the risk of dementia in T2DM patients by 35% over 8 years...
  28. ncbi Three-year efficacy of complex insulin regimens in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    N Engl J Med 361:1736-47. 2009
    ..Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited...
  29. ncbi Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus
    Luigi F Meneghini
    University of Miami Miller School of Medicine, Eleanor and Joseph Kosow Diabetes Treatment Center, Diabetes Research Institute, Miami, Florida 33136, USA
    Endocr Pract 16:588-99. 2010
    ..To compare glycemic control with add-on insulin glargine versus pioglitazone treatment in patients with type 2 diabetes...
  30. pmc Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
    M Marre
    Service d Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    Diabet Med 26:268-78. 2009
    ..To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes...
  31. ncbi Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
    W Yang
    Department of Endocrinology, China Japan Friendship Hospital, Beijing, China
    Diabetes Obes Metab 13:81-8. 2011
    ..To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India...
  32. ncbi Sulphonylurea action revisited: the post-cloning era
    F M Gribble
    Department of Clinical Biochemistry, Addenbrooke s Hospital, Hills Road, Box 232, Cambridge CB2 2QR, UK
    Diabetologia 46:875-91. 2003
    ..Further studies are still required before a final decision can be made on whether non-selective agents are appropriate for the therapy of Type 2 diabetes...
  33. ncbi Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
    F Alvarez Guisasola
    Centro de Salud La Calzada II, Gijon, Spain
    Diabetes Obes Metab 10:8-15. 2008
    ....
  34. ncbi Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study
    Mohamed Hassanein
    Betsi Cadwaladr University Health Board, Rhyl, UK
    Curr Med Res Opin 27:1367-74. 2011
    ..To compare the incidence of hypoglycaemic events (HEs) in a real-world setting in Muslim patients with type 2 diabetes mellitus fasting during Ramadan...
  35. ncbi Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers
    Juraj Stanik
    DIABGENE and Diabetes Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska 3, SK 833 06 Bratislava, Slovak Republic
    J Clin Endocrinol Metab 92:1276-82. 2007
    ..Thus, the aim of this study was to identify the incidence of PNDM in Slovakia and to switch patients to sulfonylurea (SU) where applicable...
  36. ncbi GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
    G Schernthaner
    Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 34:535-42. 2004
    ..The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice...
  37. ncbi Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, University of Oxford, Headington, Oxford, United Kingdom
    N Engl J Med 357:1716-30. 2007
    ..Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited...
  38. ncbi Activating mutations in the ABCC8 gene in neonatal diabetes mellitus
    Andrey P Babenko
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, USA
    N Engl J Med 355:456-66. 2006
    ..We hypothesized that activating mutations in ABCC8, which encodes SUR1, cause neonatal diabetes...
  39. ncbi A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with
    H C Gerstein
    Division of Endocrinology and Metabolism and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada
    Diabet Med 23:736-42. 2006
    ..However, its potential advantages suggest that it could be added earlier to achieve glycaemic goals; this possibility was tested in a clinical trial...
  40. ncbi Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications
    J P Riveline
    Department of Diabetology, Sud Francilien Hospital, Corbeil, France
    Diabetes Metab 29:207-22. 2003
    ..33 years after the UGDP study, the question of deleterious effects of the sulfoylurea (SU) is still raised. We have made a systematic review of the literature from experimental studies to clinical and epidemiological studies...
  41. ncbi Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
    M Nauck
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Bad Lauterberg, Germany
    Diabetes Obes Metab 15:204-12. 2013
    ..To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes...
  42. ncbi Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study
    B Sillars
    University of Western Australia, Nedlands, Australia
    Diabetes Obes Metab 12:757-65. 2010
    ..To determine whether combination of metformin-sulphonylurea is associated with an increased risk of cardiovascular disease (CVD) and mortality in an urban community-based cohort of type 2 patients...
  43. ncbi Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications
    Nihar R Desai
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am J Med 125:302.e1-7. 2012
    ..We aimed to evaluate temporal trends in the use of specific drugs for the initial management of type 2 diabetes and to estimate the economic consequences of non-recommended care...
  44. pmc The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
    S Al Sifri
    Al Hada Military Hospital, Taif, Saudi Arabia
    Int J Clin Pract 65:1132-40. 2011
    ..To compare the incidence of symptomatic hypoglycaemia in fasting Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan...
  45. ncbi Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Eur J Pharmacol 666:251-6. 2011
    ..Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide...
  46. ncbi The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
    D Russell-Jones
    Department of Diabetes and Endocrinology, Cedar Centre at the Royal Surrey County Hospital, Guildford, UK
    Int J Clin Pract 64:1402-14. 2010
    ..GLP-1 receptor agonists thus offer a new and potentially useful option for clinicians concerned about some of the common adverse effects of type-2 diabetes therapies...
  47. ncbi Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia
    P Spallarossa
    Department of Internal Medicine, University of Genova, Italy
    Diabetes Care 24:738-42. 2001
    ....
  48. ncbi Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study
    Laurent Azoulay
    Division of Clinical Epidemiology, SMBD Jewish General Hospital, Montreal, Quebec, Canada
    Pharmacoepidemiol Drug Saf 19:335-42. 2010
    ..To determine whether combination of sulfonylureas and metformin increases the risk of death from any cause in patients with type 2 diabetes...
  49. ncbi Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study
    Shaukat M Sadikot
    Jaslok Hospital and Research Center, 15 Dr Deshmukh Marg, Peddar Road, Mumbai 400026, India
    Diabetes Res Clin Pract 82:391-5. 2008
    ..This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas...
  50. ncbi Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
    Richard Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN, USA
    Curr Med Res Opin 25:65-75. 2009
    ....
  51. ncbi Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
    R Arechavaleta
    Hospital Especialidades Centro Medico de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
    Diabetes Obes Metab 13:160-8. 2011
    ..to evaluate the efficacy and safety of adding sitagliptin or glimepiride to the treatment regimen of patients with type 2 diabetes mellitus and inadequate glycaemic control on metformin monotherapy...
  52. ncbi Sulfonylurea-responsive diabetes in childhood
    Zohar Landau
    Diabetes Unit, E Wolfson Medical Center, Holon, Israel
    J Pediatr 150:553-5. 2007
    ..All affected individuals carried the same KCNJ11 gene mutation. In all, sulfonylurea treatment permitted cessation of insulin treatment, with improved glycemic control...
  53. ncbi Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting
    Rajat Bhushan
    Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana 70808, USA
    Diabetes Technol Ther 11:353-9. 2009
    ..We evaluated exenatide use on glycosylated hemoglobin A1c (HbA(1c)) and cardiometabolic risk factors in patients with T2DM and MetS in a single clinical practice setting...
  54. ncbi Glimepiride. A review of its use in the management of type 2 diabetes mellitus
    H D Langtry
    Adis International Limited, Auckland, New Zealand
    Drugs 55:563-84. 1998
    ..Dosage is usually started at 1 mg/day, titrated to glycaemic control at 1- to 2-week intervals to a usual dosage range of 1 to 4 mg/day (maximum 6 mg/day in the UK or 8 mg/day in the US)...
  55. ncbi Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial
    Anthony H Barnett
    Department of Diabetes, Obesity and Endocrinology, University of Birmingham and Birmingham Heartlands and Solihull NHS Trust, Bordesley Green East, Birmingham, United Kingdom
    Clin Ther 29:2333-48. 2007
    ..This study was conducted to compare the efficacy and safety profiles of exenatide and insulin glargine therapy in patients with type 2 diabetes who had not achieved glucose control with metformin or sulfonylurea monotherapy...
  56. ncbi Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients
    G Charpentier
    , Corbeil, France
    Diabet Med 18:828-34. 2001
    ..039). CONCLUSIONS: Addition of glimepiride to metformin in Type 2 diabetic patients inadequately controlled by metformin alone resulted in superior glycaemic control compared with glimepiride or metformin monotherapy...
  57. pmc Hypoglycaemia in Type 2 diabetes
    S A Amiel
    King s College London School of Medicine, London, UK
    Diabet Med 25:245-54. 2008
    ..Their use, and more prudent use of older therapies with low risk of hypoglycaemia, may help patients achieve improved glucose control for longer, and reduce the risk of diabetic complications...
  58. ncbi Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study
    S R Aravind
    Diacon Hospital, Diabetes Care and Research Centre, Bangalore, India
    Curr Med Res Opin 27:1237-42. 2011
    ..To determine the incidence of hypoglycaemia during Ramadan in Muslim subjects with type 2 diabetes treated with a sulphonylurea...
  59. ncbi Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
    S L Bowker
    Department of Public Health Sciences, School of Public Health, University of Alberta, 2 040 Health Research Innovation Facility, Edmonton, AB, Canada T6G 2E1
    Diabetologia 53:1631-7. 2010
    ..We explored the relationship between glucose-lowering agents and cancer mortality rates in type 2 diabetes patients, hypothesising a decreased risk of cancer mortality with metformin use and a dose-risk gradient for insulin therapy...
  60. ncbi Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation
    A S Slingerland
    Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, UK
    Diabet Med 25:277-81. 2008
    ..Sulphonylureas have been shown to improve glycaemic control and also motor function, but the impact on cognitive function has not been extensively addressed previously...
  61. ncbi Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
    Alan Garber
    Baylor College of Medicine, Houston, TX, USA
    Lancet 373:473-81. 2009
    ..New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder...
  62. ncbi Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus
    Maria Sara Remedi
    Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Cell Metab 9:140-51. 2009
    ....
  63. ncbi Impairment of myocardial protection in type 2 diabetic patients
    Tsung Ming Lee
    National Taiwan University College of Medicine, Department of Internal Medicine, Cardiology Section, National Taiwan University Hospital, Taipei, Taiwan 10002
    J Clin Endocrinol Metab 88:531-7. 2003
    ..Restitution of a preconditioning response in glimepiride-treated patients may be the potential beneficial mechanism...
  64. ncbi Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
    Henriette T Horsdal
    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Diabetes Metab Res Rev 25:515-22. 2009
    ..The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI...
  65. ncbi Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    David M Kendall
    International Diabetes Center and University of Minnesota, Minmneapolis, MN, USA
    Diabetes Care 28:1083-91. 2005
    ..This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy...
  66. ncbi Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus
    Hans U Janka
    Klinikum Bremen Nord, Bremen, Germany
    J Am Geriatr Soc 55:182-8. 2007
    ..To compare initiation of insulin therapy by adding once-daily insulin glargine to oral antidiabetic agents (OADs) with switching patients to premixed 30% regular, 70% human neutral protamine hagedorn insulin (70/30) without OADs...
  67. ncbi Cardiovascular effects of conventional sulfonylureas and glimepiride
    K Geisen
    Pharma Research, Hoechst AG, Germany
    Horm Metab Res 28:496-507. 1996
    ..The presented data confirm that glimepiride at equivalent blood glucose decreasing doses has less cardiovascular activity than conventional sulfonylureas...
  68. ncbi Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis
    Charalambos Antoniades
    A Cardiology Department, Athens University Medical School, Athens, Greece
    Clin Cardiol 30:295-300. 2007
    ..Type 2 diabetes mellitus (T2DM) is characterized by endothelial dysfunction, increased thrombogenicity and abnormal inflammatory response...
  69. pmc The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl
    G Muller
    Aventis Pharma Germany, Frankfurt
    Mol Med 6:907-33. 2000
    ....
  70. ncbi Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)
    B Karamanos
    Diabetes Center, 2nd Department of Internal Medicine and Research Laboratory, National University of Athens, Hippokration General Hospital, Athens, Greece
    Curr Med Res Opin 27:303-13. 2011
    ..To explore whether the improvement of lipid profile and glycaemic control observed in randomized control trials with pioglitazone (PIO) is replicated under conditions of general clinical practice...
  71. pmc Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:1938-46. 2010
    ..This objective of the current study was to determine the association between HCC risk and diabetes duration and type of diabetes treatment...
  72. ncbi Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes
    Günter Müller
    Sanofi Aventis Pharma, Frankfurt am Main, Germany
    Eur J Pharmacol 597:6-18. 2008
    ....
  73. ncbi Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy
    P M Thomas
    Department of Medical Specialties, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Science 268:426-9. 1995
    ..Both mutations resulted in aberrant processing of the RNA sequence and disruption of the putative second nucleotide binding domain of the SUR protein. Abnormal insulin secretion in PHHI appears to be caused by mutations in the SUR gene...
  74. ncbi Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus
    Michael Davidson
    Pritzker School of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Circulation 117:2123-30. 2008
    ..Compared with glimepiride, pioglitazone has been shown to slow the progression of atherosclerosis measured by CIMT in patients with type 2 diabetes mellitus...
  75. ncbi Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene
    G Tonini
    Diabetologia 49:2210-3. 2006
  76. ncbi The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
    Kevin M Pantalone
    Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue NA10, Cleveland, OH, 44195, USA
    Acta Diabetol 46:145-54. 2009
    ..In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas...
  77. ncbi The duration of sulfonylurea treatment is associated with β-cell dysfunction in patients with type 2 diabetes mellitus
    Mi Seon Shin
    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Diabetes Technol Ther 14:1033-42. 2012
    ..This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up...
  78. pmc Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel
    Kevin S C Hamming
    Department of Pharmacology, Alberta Diabetes Institute, University of Alberta, Alberta, Canada
    Diabetes 58:2419-24. 2009
    ..Furthermore, there have been no studies of the S1369A variant or the combined effect of the two on K(ATP) channel function...
  79. ncbi Persistence patterns with oral antidiabetes drug treatment in newly treated patients--a population-based study
    Jean Pierre Grégoire
    Faculty of Pharmacy, Universite Laval, Quebec, QC, Canada
    Value Health 13:820-8. 2010
    ..We assessed persistence patterns with oral antidiabetes drug (OAD) in patients newly dispensed with different OAD classes...
  80. ncbi Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    E Ferrannini
    Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa, Pisa, Italy
    Diabetes Obes Metab 11:157-66. 2009
    ..The primary objective was to demonstrate non-inferiority of vildagliptin vs. glimepiride in glycosylated haemoglobin (HbA(1c)) reduction at week 52...
  81. pmc Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]
    Abdul Basit
    Department of Medicine, Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi, Pakistan
    Vasc Health Risk Manag 8:463-72. 2012
    ..It is effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels and is a useful, cost-effective treatment option for managing type 2 diabetes mellitus...
  82. ncbi Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
    Victor Lawrence Roberts
    Clin Ther 27:1535-47. 2005
    ..This study evaluated the efficacy and tolerability of glimepiride in patients with type 2 diabetes mellitus that was inadequately controlled with a combination of immediate- or extended-release metformin and a thiazolidinedione...
  83. ncbi The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide
    M Massi-Benedetti
    Department of Internal Medicine and Endocrine and Metabolic Science, University of Perugia, Italy
    Horm Metab Res 28:451-5. 1996
    ....
  84. ncbi Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents
    Stephanie T de Dios
    Cell Biology of Diabetes Laboratory, Baker Heart Research Institute, PO Box 6492, Melbourne, Victoria 8008, Australia
    J Diabetes Complications 21:108-17. 2007
    ..The data indicate that TZDs show anti-atherogenic actions through the modification of proteoglycan structure, leading to a possible reduction in lipid retention in the vessel wall...
  85. ncbi Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor
    N Inagaki
    Division of Molecular Medicine, Chiba University School of Medicine, Japan
    Science 270:1166-70. 1995
    ..Gene mapping data show that these two potassium channel subunit genes are clustered on human chromosome 11 at position 11p15.1...
  86. ncbi Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes
    Takashi Kadowaki
    Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Japan
    Endocr J 56:415-24. 2009
    ..044, trend test). Over 12 weeks, exenatide dose-dependently improved glycemic control in Japanese patients with type 2 diabetes...
  87. ncbi Sulfonylurea stimulation of insulin secretion
    Peter Proks
    University Laboratory of Physiology, Oxford University, UK
    Diabetes 51:S368-76. 2002
    ..We also clarify the mechanism by which MgADP produces an apparent increase of sulfonylurea efficacy on channels containing SUR1 (but not SUR2)...
  88. ncbi Sulfonylurea use before stroke does not influence outcome
    Christopher G Favilla
    Department of Neurology, University of Pennsylvania Medical Center, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Stroke 42:710-5. 2011
    ..Human data on sulfonylureas in acute stroke are sparse and conflicting. We aimed to measure the potential neuroprotective effect of prestroke sulfonylurea use in diabetic patients...
  89. ncbi Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons"
    R J Heine
    Department of Endocrinology, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, The Netherlands
    Horm Metab Res 28:522-6. 1996
    ..These observations need further confirmation. Of clinical importance is the frequent occurrence of hypoglycaemia for which several risk factors are recognized...
  90. ncbi Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study
    Raimund Weitgasser
    1st Department of Medicine, St Johanns Spital Salzburg General Hospital, Salzburg, Austria
    Diabetes Res Clin Pract 61:13-9. 2003
    ..005, respectively). Therefore, once daily glimepiride provides effective glycaemic control, and may have advantages over other sulphonylureas, because it exhibits weight neutralizing/reducing effects in patients with Type 2 diabetes...
  91. ncbi Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Nutr Metab 17:143-50. 2004
    ..These reductions may be owing to improved glucose metabolism, but it cannot be excluded that these drugs have a direct effect on additional metabolic parameters...
  92. ncbi Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis
    J A Pugh
    Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas 78284
    Diabetes Care 15:953-9. 1992
    ..To assess the efficacy of combination therapy with insulin and sulfonylurea in the treatment of NIDDM...
  93. pmc Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans
    Benjamin A Cooperberg
    Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, Missouri, USA
    Diabetes Care 32:2275-80. 2009
    ..Given evidence of both indirect and direct signaling, we tested the hypothesis that increased beta-cell-mediated signaling of alpha-cells negates direct alpha-cell signaling in the regulation of glucagon secretion in humans...
  94. ncbi Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
    K Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama 701 0192, Japan
    Diabetes Obes Metab 12:341-7. 2010
    ..Sulphonylureas (SUs) are often used as first-line treatments for type 2 diabetes in Japan, hence it is important to study new antidiabetic drugs in combination with SUs in Japanese patients...
  95. ncbi Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study
    Mary Margaret Huizinga
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Pharmacoepidemiol Drug Saf 19:1108-12. 2010
    ..Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI)...
  96. ncbi The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus
    H E Clark
    Oxford Diabetes Centre, Radcliffe Infirmary, United Kingdom
    Horm Metab Res 28:445-50. 1996
    ..The magnitude and hence, the clinical relevance of a selective beta-cytotropic action, determined by blood glucose concentration, remains to be demonstrated...
  97. pmc Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
    Scot H Simpson
    Institute of Health Economics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta
    CMAJ 174:169-74. 2006
    ..The purpose of this study was to determine if the risk of death changes with level of exposure to sulfonylurea drugs...
  98. ncbi Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group
    D G Dills
    Department of Medicine, University of Wisconsin, Madison, USA
    Horm Metab Res 28:426-9. 1996
    ..Similar decreases in both fasting plasma glucose and HbA1C were found using glimepiride and glyburide. There was a lower incidence of hypoglycemia with glimepiride than glyburide...
  99. ncbi Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients
    B Rosenkranz
    Hoechst AG, Frankfurt, Germany
    Horm Metab Res 28:434-9. 1996
    ..Studies described here show that the pharmacokinetics of glimepiride are altered in renal disease but may not be seriously affected in patients with liver disease...
  100. ncbi Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study
    S Martin
    Clinical Department, German Diabetes Centre at the Heinrich Heine University, Auf m Hennekamp 65, 40225, Dusseldorf, Germany
    Diabetologia 46:1611-7. 2003
    ..Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice...

Research Grants42

  1. Educational Disparities in Diabetes Complications
    Andrew Karter; Fiscal Year: 2006
    ..abstract_text> ..
  2. Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
    Stephen Davis; Fiscal Year: 2008
    ....
  3. Clinical and Translational Science Center at the University of New Mexico
    Mark Burge; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  4. Leptin and insulin action in the brain; role in obesity
    Kevin Niswender; Fiscal Year: 2007
    ..These aims also provide the background and training necessary for the development of an independent research program and will be conducted in the context of rich training environment ..
  5. Reactive astrocytes from gliotic capsule
    J Marc Simard; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  6. Regulation of Cortisol Metabolism and Fat Patterning
    Jonathan Purnell; Fiscal Year: 2007
    ..abstract_text> ..
  7. Glucosensing neurons in health, obesity & diabetes
    Vanessa Routh; Fiscal Year: 2008
    ..This will facilitate the development of new and effective treatments for these serious diseases of the modern world. ..
  8. Predictors and limitations of metformin as the initial agent in type 2 diabetes.
    Lydie Pani; Fiscal Year: 2008
    ..Improving glucose control [unreadable] is extremely important in order to improve the long-term health of the 20 million people with T2DM in the US. [unreadable] [unreadable] [unreadable] [unreadable]..
  9. Using Systems Biology to Understand Islet Adaptation and Failure Diabetes
    Charles F Burant; Fiscal Year: 2010
    ..The studies will also provide the first insights into the ways in which human islets react to specific nutrient challenges. ..
  10. Brain insulin and leptin resistance in obesity
    Kevin Niswender; Fiscal Year: 2008
    ..Aim 4: To determine if genetic enhancement of the hypothalamic PI3K pathway enhances insulin and leptin sensitivity and attenuates DIO. ..
  11. Inflammation, proteolysis and IL-1beta receptor inhibition in CHD patients
    ADRIANA HUNG; Fiscal Year: 2008
    ..We want to test if reducing inflammation with an anti-inflammatory treatment will reduce muscle loss in dialysis patients. [unreadable] [unreadable] [unreadable]..
  12. Structure and Regulation of Ghrelin in Obesity
    Jonathan Q Purnell; Fiscal Year: 2010
    ..Results from these studies will broaden our understanding of the brain-gut axis involved in body weight regulation by clarifying the regulation of ghrelin levels and structure in lean and obese individuals. ..
  13. Insulin Resistance and Hepatic Steatosis in Hepatitis C
    Charles F Burant; Fiscal Year: 2010
    ..abstract_text> ..
  14. ABCC8/KCNJ11 Mechanisms and Diabetes
    Andrey P Babenko; Fiscal Year: 2010
    ..The proposed studies of these mutant receptors will reveal a novel diabetogenic mechanism and result in a new and better treatment of neonatal diabetes. ..
  15. CRP, Diabetes, Atherothrombosis
    Ishwarlal Jialal; Fiscal Year: 2010
    ..CRP augments oxidative stress and inflammation in the diabetic milieu will eventually lead to therapies targeted at reducing inflammation and oxidative stress in diabetes and resulting in a decrease in vasculopathies ..
  16. Sex steroid, HPA regulation, and fat patterning
    Jonathan Purnell; Fiscal Year: 2003
    ..abstract_text> ..
  17. Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
    Robert Henry; Fiscal Year: 2004
    ..abstract_text> ..
  18. RANDOMIZED TRIAL OF FOLATE AND COLORECTAL ADENOMA
    Edward Giovannucci; Fiscal Year: 2003
    ..abstract_text> ..
  19. ASYMMETRIC SYNTHESIS OF IONOPHORE/MACROLIDE ANTIBIOTICS
    David Evans; Fiscal Year: 2005
    ..Our goal has been to set in place all of the reactions necessary for the rapid assemblage of any polyketide target structure. ..
  20. Do Free Glucose Test Strips Increase Self-Monitoring?
    Andrew Karter; Fiscal Year: 2003
    ..Proposal strengths also include a longitudinal design, substantial statistical power, low cost data acquisition, and an ethnically diverse population with uniform access to care. ..
  21. Hepatitis Virus, Alcohol Exposure and Oxidative Stress
    Manal Hassan; Fiscal Year: 2002
    ..Serum Se, GPx activity, lipid peroxides and oxidative DNA damage will be measured in relation to HCV and alcohol intake history. ..
  22. ASYMMETRIC SYNTHESIS OF VANCOMYCIN ANTIBIOTICS
    David Evans; Fiscal Year: 2001
    ..During the course of this project we intend to confirm (correct) the absolute stereochemical assignments of the principal members of this family by total synthesis. ..
  23. CELL SURFACE METABOLISM OF MACROPHAGE DERIVED APO E
    Theodore Mazzone; Fiscal Year: 2001
    ..In this Specific Aim we will more thoroughly examine the metabolism of LDL and ALDL as it is influenced by the cell surface pool of macrophage derived apo E. ..
  24. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  25. CORTISOL, CENTRAL OBESITY, AND INSULIN RESISTANCE
    Jonathan Purnell; Fiscal Year: 2003
    ....
  26. Synthesis of Polyketides and Terpenes
    David A Evans; Fiscal Year: 2010
    ..As a consequence, organic synthesis is a critical discipline that continues to have an important impact on the fields of both medicine and biology. ..
  27. Ethanol on Overnight Glucose Regulation in Diabetes
    Mark Burge; Fiscal Year: 2008
    ..These important studies will provide a scientific basis for the prevention of overnight hypoglycemia (and the attendant cost savings) by providing mechanistic insights into the causes of nocturnal hypoglycemia. [unreadable] [unreadable]..
  28. Diabetes and Cardiovascular Risks in Primary Care
    Michael Parchman; Fiscal Year: 2005
    ....
  29. DIET AND GENETIC INTERACTIONS IN PROSTATE CANCER
    Edward Giovannucci; Fiscal Year: 2001
    ..The buccal brushings, along with providing the basis for the specific aims in this application, will allow for the rapid testing of future specific hypotheses. ..
  30. PATHOPHYSIOLOGY OF NICOTINE IN CEREBRAL BLOOD VESSELS
    J Simard; Fiscal Year: 2004
    ....
  31. Glucosensing Neurons in Euglycemia, Hypoglycemia & HAAF
    Vanessa Routh; Fiscal Year: 2005
    ..This will facilitate the development of new and effective treatments for Type I diabetes mellitus and its major modern complication hypoglycemia. ..
  32. Macrophage Cholesterol Metabolism and ApoE Synthesis
    Theodore Mazzone; Fiscal Year: 2007
    ..abstract_text> ..
  33. Hypothalamic fMRI response to nutrients
    Jonathan Purnell; Fiscal Year: 2007
    ..These studies will help us to better understand why changes in the diet might lead to weight gain or loss. [unreadable] [unreadable] [unreadable]..
  34. CEREBROVASCULAR ION CHANNELS IN HYPERTENSION
    J Marc Simard; Fiscal Year: 2007
    ..abstract_text> ..
  35. High Dose Alpha Tocopherol and Carotid Atherosclerosis
    Ishwarlal Jialal; Fiscal Year: 2004
    ..This study has the additional novelty of correlating biomarkers of oxidative stress and inflammation with a cardiovascular endpoint and will establish whether high dose AT decreases atherosclerosis progression. ..
  36. Cyclooxygenase Pathway and Diabetic Neuropathy
    Rodica Pop Busui; Fiscal Year: 2005
    ..abstract_text> ..
  37. GLUCOCORTICOIDS, HYPOGLYCEMIA & BRAIN GLUCOSE TRANSPORT
    Anthony McCall; Fiscal Year: 2001
    ..These studies should provide insight into hypoglycemia's impact upon the brain. They may potentially lead to safer was to achieve good diabetes control. ..
  38. Ethnic Disparities in Diabetes Complications
    Andrew Karter; Fiscal Year: 2008
    ..abstract_text> ..
  39. Adipocyte Lipid Metabolism and ApoE Expression
    Theodore Mazzone; Fiscal Year: 2009
    ..For these studies, adipose tissue will be collected from the gluteal and abdominal subcutaneous regions, and from the intraperitoneal visceral region, of patients undergoing bariatric surgery;and utilized for isolation of adipocytes. ..
  40. Characteristics and Costs of Impaired Fasting Glucose
    Gregory Nichols; Fiscal Year: 2005
    ..Finally, we will calculate and compare the costs of medical care for patients in each FPG stage, and estimate multivariate models to identify factors that contribute to medical costs in each stage. ..